May 26, 2017 / 4:26 PM / 3 months ago

BRIEF-Kite receives U.S. FDA priority review for Axicabtagene Ciloleucel

May 26 (Reuters) - Kite Pharma Inc

* Kite receives U.S. Food and Drug Administration priority review for Axicabtagene Ciloleucel

* Kite Pharma Inc - Prescription Drug User Fee Act (PDUFA) set for November 29, 2017

* Kite Pharma Inc - Biologics License Application submission based on primary analysis of ZUMA-1 Phase 2 trial

* Kite Pharma Inc - ‍Expects to submit its Market Authorization Application (MAA) of Axicabtagene Ciloleucel with European Medicines Agency in Q3 of 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below